{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Robert+Halfon&min-answer.dateOfAnswer=2019-05-02&answer.answerText=%3Cp%3EBetween+1+January+2020+and+14+October+2022%2C+members+of+the+Voluntary+Scheme+for+Branded+Medicines+Pricing+and+Access+have+received+approval+for+an+increase+to+the+National+Health+Service+list+price+for+35+medicines%2C+for+120+presentations.+The+majority+of+price+increases+have+been+concentrated+in+specific+market+segments+particularly+impacted+by+global+cost+increases+in+the+active+pharmaceutical+ingredient.%3C%2Fp%3E%3Cp%3EPrice+increase+requests+are+assessed+in+line+with+Scheme%E2%80%99s+rules%2C+which+ensure+companies+cannot+make+excess+profits+by+setting+a+return+on+sales+target+of+6%25+for+standard+price+increase+requests.%3C%2Fp%3E", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?tablingMemberPrinted.=Robert+Halfon&min-answer.dateOfAnswer=2019-05-02&answer.answerText=%3Cp%3EBetween+1+January+2020+and+14+October+2022%2C+members+of+the+Voluntary+Scheme+for+Branded+Medicines+Pricing+and+Access+have+received+approval+for+an+increase+to+the+National+Health+Service+list+price+for+35+medicines%2C+for+120+presentations.+The+majority+of+price+increases+have+been+concentrated+in+specific+market+segments+particularly+impacted+by+global+cost+increases+in+the+active+pharmaceutical+ingredient.%3C%2Fp%3E%3Cp%3EPrice+increase+requests+are+assessed+in+line+with+Scheme%E2%80%99s+rules%2C+which+ensure+companies+cannot+make+excess+profits+by+setting+a+return+on+sales+target+of+6%25+for+standard+price+increase+requests.%3C%2Fp%3E", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Robert+Halfon&min-answer.dateOfAnswer=2019-05-02&answer.answerText=%3Cp%3EBetween+1+January+2020+and+14+October+2022%2C+members+of+the+Voluntary+Scheme+for+Branded+Medicines+Pricing+and+Access+have+received+approval+for+an+increase+to+the+National+Health+Service+list+price+for+35+medicines%2C+for+120+presentations.+The+majority+of+price+increases+have+been+concentrated+in+specific+market+segments+particularly+impacted+by+global+cost+increases+in+the+active+pharmaceutical+ingredient.%3C%2Fp%3E%3Cp%3EPrice+increase+requests+are+assessed+in+line+with+Scheme%E2%80%99s+rules%2C+which+ensure+companies+cannot+make+excess+profits+by+setting+a+return+on+sales+target+of+6%25+for+standard+price+increase+requests.%3C%2Fp%3E&_metadata=all", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Robert+Halfon&min-answer.dateOfAnswer=2019-05-02&_page=0&answer.answerText=%3Cp%3EBetween+1+January+2020+and+14+October+2022%2C+members+of+the+Voluntary+Scheme+for+Branded+Medicines+Pricing+and+Access+have+received+approval+for+an+increase+to+the+National+Health+Service+list+price+for+35+medicines%2C+for+120+presentations.+The+majority+of+price+increases+have+been+concentrated+in+specific+market+segments+particularly+impacted+by+global+cost+increases+in+the+active+pharmaceutical+ingredient.%3C%2Fp%3E%3Cp%3EPrice+increase+requests+are+assessed+in+line+with+Scheme%E2%80%99s+rules%2C+which+ensure+companies+cannot+make+excess+profits+by+setting+a+return+on+sales+target+of+6%25+for+standard+price+increase+requests.%3C%2Fp%3E", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Robert+Halfon&min-answer.dateOfAnswer=2019-05-02&answer.answerText=%3Cp%3EBetween+1+January+2020+and+14+October+2022%2C+members+of+the+Voluntary+Scheme+for+Branded+Medicines+Pricing+and+Access+have+received+approval+for+an+increase+to+the+National+Health+Service+list+price+for+35+medicines%2C+for+120+presentations.+The+majority+of+price+increases+have+been+concentrated+in+specific+market+segments+particularly+impacted+by+global+cost+increases+in+the+active+pharmaceutical+ingredient.%3C%2Fp%3E%3Cp%3EPrice+increase+requests+are+assessed+in+line+with+Scheme%E2%80%99s+rules%2C+which+ensure+companies+cannot+make+excess+profits+by+setting+a+return+on+sales+target+of+6%25+for+standard+price+increase+requests.%3C%2Fp%3E", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Robert+Halfon&min-answer.dateOfAnswer=2019-05-02&answer.answerText=%3Cp%3EBetween+1+January+2020+and+14+October+2022%2C+members+of+the+Voluntary+Scheme+for+Branded+Medicines+Pricing+and+Access+have+received+approval+for+an+increase+to+the+National+Health+Service+list+price+for+35+medicines%2C+for+120+presentations.+The+majority+of+price+increases+have+been+concentrated+in+specific+market+segments+particularly+impacted+by+global+cost+increases+in+the+active+pharmaceutical+ingredient.%3C%2Fp%3E%3Cp%3EPrice+increase+requests+are+assessed+in+line+with+Scheme%E2%80%99s+rules%2C+which+ensure+companies+cannot+make+excess+profits+by+setting+a+return+on+sales+target+of+6%25+for+standard+price+increase+requests.%3C%2Fp%3E", "items" : [{"_about" : "http://data.parliament.uk/resources/1521780", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1521780/answer", "answerText" : {"_value" : "

Between 1 January 2020 and 14 October 2022, members of the Voluntary Scheme for Branded Medicines Pricing and Access have received approval for an increase to the National Health Service list price for 35 medicines, for 120 presentations. The majority of price increases have been concentrated in specific market segments particularly impacted by global cost increases in the active pharmaceutical ingredient.<\/p>

Price increase requests are assessed in line with Scheme\u2019s rules, which ensure companies cannot make excess profits by setting a return on sales target of 6% for standard price increase requests.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4423", "label" : {"_value" : "Biography information for Will Quince"} } , "answeringMemberConstituency" : {"_value" : "Colchester"} , "answeringMemberPrinted" : {"_value" : "Will Quince"} , "dateOfAnswer" : {"_value" : "2022-11-03", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2022-11-03T13:28:21.187Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2022-10-13", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "NHS: Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, how many medicine by presentations included within the Voluntary Patient Access Scheme have had NHS List Price increase approved by their Department since 1 January 2020; and what was the average percentage increase for any such increases.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3985", "label" : {"_value" : "Biography information for Robert Halfon"} } , "tablingMemberConstituency" : {"_value" : "Harlow"} , "tablingMemberPrinted" : [{"_value" : "Robert Halfon"} ], "uin" : "62789"} ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 1, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]} }